Description_x000D_ General description_x000D_ Tigecycline is used to treat complicated skin and skin structure infections (cSSSI) and complicated intraabdominal infections._x000D_ Application_x000D_ TIGECYCLINE HYDRATE has been used:_x000D_ • for antibiotic susceptibility testing_x000D_ • to study its effects on multiple nonsmall cell lung cancer (NSCLC) cell lines_x000D_ • to evaluate its effects on the binding of fluoroquinolones to human serum albumin_x000D_ • as a standard to investigate the penetration of tigecycline into cornea, aqueous humor and vitreous humor_x000D_ Packaging_x000D_ 5, 25 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ Tigecycline is a broad spectrum glycylcycline antibiotic. Tigecycline is bacteriostatic, that inhibits protein synthesis by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation. Tigecycline is active against resistant strains of gram-positive and gram-negative bacteria, avoiding the two most common mechanisms of resistance to the tetracycline antimicrobials: tetracycline efflux pump proteins and ribosomal protection proteins._x000D_ Features and Benefits_x000D_ This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®Pfizer), a collection of 90 Pfizer-developed drugs and research tools. Click here to learn more._x000D_ Other Notes_x000D_ This compound was developed by Pfizer for Immunology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer._x000D_ To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ air sensitive_x000D_ Legal Information_x000D_ Sold for research purposes under agreement from Pfizer Inc._x000D_ LOPAC is a registered trademark of Sigma-Aldrich Co. LLC_x000D_ Pfizer is a registered trademark of Pfizer, Inc.